This 2016 review by Jacqueline Jonklaas provides a critical assessment of the benefits and risks associated with combination therapy using levothyroxine (LT4) and liothyronine (LT3) for the treatment of hypothyroidism. Although LT4 monotherapy remains the standard of care, some patients continue to experience residual symptoms despite normal serum TSH levels,
This 2018 cross-sectional online survey assessed treatment satisfaction among 12,146 hypothyroid patients in the U.S. Participants reported their experiences with levothyroxine (LT4) monotherapy, LT4 plus liothyronine (LT3) combination therapy, or desiccated thyroid extract (DTE). Patients using DTE reported significantly greater satisfaction with their treatment, including better outcomes in weight management,
This quasi-randomized, single-blind pilot study investigated the effects of levothyroxine/liothyronine combination therapy versus levothyroxine monotherapy on sexual function and depressive symptoms in 39 premenopausal women with hypothyroidism who continued to experience symptoms despite normalized thyroid hormone levels. Over six months, the combination therapy group showed significant improvements in sexual desire
This study examined the 24-hour hormone profiles of TSH, free T3, and free T4 in 20 hypothyroid patients, comparing those on combined T3/T4 therapy (n=10) with those on T4 monotherapy (n=10). Patients on combined therapy experienced a 42% increase in fT3 levels within 4 hours post-dose, while those on T4
The article titled “Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document” examines the inconsistent benefits of levothyroxine (LT4) and liothyronine (LT3) combination therapy for hypothyroidism, despite its widespread use due to patient-reported benefits. A joint conference by the American, British, and European Thyroid Associations reviewed clinical evidence
A randomized, double-blind, placebo-controlled trial examined the cardiometabolic effects of combined levothyroxine (LT4) and liothyronine (LT3) therapy versus LT4 alone in athyreotic patients without cardiovascular risk factors. The study included 38 patients with postsurgical hypothyroidism, of whom 24 completed one year of treatment. The LT4+LT3 group demonstrated a significant improvement
This study examined the effects of a single 50-mcg dose of liothyronine (T3) on thyroid hormones, thyroid-stimulating hormone (TSH), and vital signs over four days in 12 healthy euthyroid participants. Triiodothyronine levels peaked at 2.5 hours post-administration, while heart rate significantly increased within 5 hours (p=0.009). TSH suppression was observed
The article titled “Combination treatment with T4 and T3: toward personalized replacement therapy in hypothyroidism?” from the Journal of Clinical Endocrinology & Metabolism (2012, PMID: 22593590) reviews evidence on combination therapy with levothyroxine (T4) and liothyronine (T3) for hypothyroidism. While standard T4 monotherapy effectively normalizes TSH levels in most patients,
The randomized controlled trial titled “Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism” (JAMA, 2003, PMID: 14665656) investigated whether combination therapy with levothyroxine (T4) and liothyronine (T3) provided additional benefits compared to T4 alone in patients with primary hypothyroidism. In this study of 46 patients aged 24–65
The meta-analysis titled “Combined T4 + T3 Therapy Versus T4 Monotherapy Effect on Psychological Health in Hypothyroidism” (Clinical Endocrinology, 2022, PMID: 35445422) evaluated the psychological effects of combined levothyroxine (T4) and liothyronine (T3) therapy compared to T4 monotherapy across nine randomized controlled trials involving 1,210 hypothyroid patients. The analysis found
